https://scholars.lib.ntu.edu.tw/handle/123456789/638368
Title: | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer | Authors: | Chi, Kim N Rathkopf, Dana Smith, Matthew R Efstathiou, Eleni Attard, Gerhardt Olmos, David Lee, Ji Youl Small, Eric J Pereira de Santana Gomes, Andrea J Roubaud, Guilhem Saad, Marniza Zurawski, Bogdan Sakalo, Valerii Mason, Gary E Francis, Peter Wang, George Wu, Daphne Diorio, Brooke Lopez-Gitlitz, Angela Sandhu, Shahneen YU-CHIEH TSAI |
Issue Date: | 20-Jun-2023 | Journal Volume: | 41 | Journal Issue: | 18 | Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Abstract: | Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/638368 | ISSN: | 0732183X | DOI: | 10.1200/JCO.22.01649 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.